Related Experiment Videos
[Treatment of nephrotic syndrome in IgA nephropathy with IgG pulsed doses]
D Maksić1, M Marić, J Dimitrijević
1Vojnomedicinska akademija, Klinika za nefrologiju, Beograd.
The preliminary results of nephrotic syndrome treatment in IgA nephropathy (IgAN) with pulse IgG doses have been presented. The diagnosis of IgAN has been made exclusively by percutaneous ultrasonically guided biopsy of kidneys, on the basis of characteristic finding of immunofluorescent and light microscopy. Histopathological changes were classified upon the Classification of World Health Organization for IgAN with the calculation of average glomerular, vascular and indices of interstitial fibrosis and tubular athrophy. The therapy with IgG was applied in 3 patients with nephrotic syndrome in complex of IgAN with minimal histologic changes, i.e. diffuse mesangioproliferative glomerulonephritis. Initial pulse dose of IgG was 0.4 g/kg and it was administered in slow intravenous infusion for three days running during three months. The therapy of maintenance consisted of intramuscular administration of IgG in the dose of 2.5 g, twice a month, for the next three months. After the six-month treatment, clinical and biochemical remission was achieved in the patient with minimal histologic changes, and in the other two patients with diffuse mesangioproliferative glomerulonephritis the effect of therapy was revealed in proteinuria decrease for over 50% and the preserved renal function on the level before the therapy has started. Temporary increase of creatinine serum concentration was registered in two our patients. Preliminary results of pulse therapy with immunoglobulin G, although obtained on the small patient number, imply its powerful immunomodulatory features, which complexity and action levels should be more investigated.
The preliminary results of nephrotic syndrome treatment in IgA nephropathy (IgAN) with pulse IgG doses have been presented. The diagnosis of IgAN has been made exclusively by percutaneous ultrasonically guided biopsy of kidneys, on the basis of characteristic finding of immunofluorescent and light microscopy. Histopathological changes were classified upon the Classification of World Health Organization for IgAN with the calculation of average glomerular, vascular and indices of interstitial fibrosis and tubular athrophy. The therapy with IgG was applied in 3 patients with nephrotic syndrome in complex of IgAN with minimal histologic changes, i.e. diffuse mesangioproliferative glomerulonephritis. Initial pulse dose of IgG was 0.4 g/kg and it was administered in slow intravenous infusion for three days running during three months. The therapy of maintenance consisted of intramuscular administration of IgG in the dose of 2.5 g, twice a month, for the next three months. After the six-month treatment, clinical and biochemical remission was achieved in the patient with minimal histologic changes, and in the other two patients with diffuse mesangioproliferative glomerulonephritis the effect of therapy was revealed in proteinuria decrease for over 50% and the preserved renal function on the level before the therapy has started. Temporary increase of creatinine serum concentration was registered in two our patients. Preliminary results of pulse therapy with immunoglobulin G, although obtained on the small patient number, imply its powerful immunomodulatory features, which complexity and action levels should be more investigated.